Mylan Launches Wixela Inhub, the First Generic of ADVAIR DISKUS

Mylan N.V. announced the launch of the first FDA-approved therapeutically equivalent, substitutable generic of ADVAIR DISKUS, Wixela Inhub (fluticasone propionate and salmeterol inhalation powder, USP), approved by the U.S. Food and Drug Administration (FDA) through the Abbreviated New Drug Application (ANDA) pathway. Wixela Inhub is indicated for certain patients with asthma or chronic obstructive pulmonary disease (COPD). All three strengths of Wixela Inhub will be offered at a wholesale acquisition cost* 70 percent less than ADVAIR DISKUS and 67 percent less than GSK’s authorized generic version which launched on Feb. 8. The wholesale acquisition costs of Wixela Inhub 100 mcg/50 mcg, 250 mcg/50 mcg and 500 mcg/50 mcg strengths are USD 93.71, USD 116.44 and USD 153.14, respectively.

Mylan’s Chief Commercial Officer Tony Mauro commented, “We’ve had numerous discussions with customers about the need for a unique launch strategy for the first substitutable generic of ADVAIR DISKUS that increases affordability to all in our healthcare system. We trust that by launching Wixela Inhub at a significantly discounted list price, we will demonstrate the savings that generics can deliver for patients through reduced out-of-pocket costs, as well as the U.S. healthcare system overall.”

In addition, Mylan will offer patient services to provide training and education about the treatment and device. Wixela Inhub is indicated for the twice daily treatment of asthma in patients age 4 and older not adequately controlled on long-term asthma medications or whose disease warrants initiation of treatment with both inhaled corticosteroids and long-acting beta agonists; maintenance treatment of COPD; and the reduction of COPD exacerbations in patients with a history of exacerbations. It is not indicated for the relief of acute bronchospasm. – Medical Buyer Bureau